PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1786682
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1786682
Global Hepatitis E Diagnostic Tests Market to Reach US$67.8 Million by 2030
The global market for Hepatitis E Diagnostic Tests estimated at US$55.4 Million in the year 2024, is expected to reach US$67.8 Million by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. ELISA HEV IGM Tests Type, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$29.6 Million by the end of the analysis period. Growth in the ELISA HEV IGG Tests Type segment is estimated at 2.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$15.1 Million While China is Forecast to Grow at 6.6% CAGR
The Hepatitis E Diagnostic Tests market in the U.S. is estimated at US$15.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.7 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.
Hepatitis E, a liver infection caused by the hepatitis E virus (HEV), is becoming an increasing public health concern, particularly in developing regions with limited access to clean water and sanitation. The disease primarily spreads through contaminated water sources, making it a significant challenge in countries with poor infrastructure. Diagnostic tests play a crucial role in detecting HEV infections, facilitating timely treatment, and preventing outbreaks. The growing prevalence of hepatitis E in both endemic and non-endemic regions has heightened the demand for accurate and rapid diagnostic solutions. Governments and healthcare organizations are investing in screening programs to mitigate the spread of HEV, driving the expansion of the hepatitis E diagnostic tests market.
The hepatitis E diagnostic market is witnessing rapid technological advancements, with improvements in serological assays, polymerase chain reaction (PCR) techniques, and point-of-care testing solutions. The development of enzyme-linked immunosorbent assays (ELISA) has enhanced the accuracy and efficiency of detecting HEV antibodies, allowing for early diagnosis and disease monitoring. Additionally, the introduction of molecular diagnostic techniques, such as real-time PCR, has enabled precise identification of HEV RNA, aiding in the differentiation of acute and chronic infections. The emergence of rapid test kits is further improving access to hepatitis E diagnostics, particularly in resource-limited settings. These innovations are enhancing the reliability and accessibility of hepatitis E testing, contributing to improved disease control efforts.
The rising incidence of hepatitis E infections, increasing global travel, and growing awareness about viral hepatitis have fueled the demand for hepatitis E diagnostic tests. Governments and healthcare agencies are implementing screening programs in high-risk populations, such as pregnant women and immunocompromised individuals, to prevent complications associated with HEV infections. The expansion of point-of-care diagnostics in rural areas has also contributed to improved disease detection and management. Additionally, advancements in diagnostic automation are reducing turnaround times, enabling faster decision-making in clinical settings. As global health organizations prioritize hepatitis prevention and control, the demand for HEV diagnostic solutions is expected to grow significantly.
The growth in the hepatitis E diagnostic tests market is driven by increasing disease prevalence, advancements in diagnostic technologies, and government initiatives aimed at improving viral hepatitis surveillance. The expansion of healthcare infrastructure in developing countries is also facilitating greater access to hepatitis testing. Additionally, the rising investment in research and development for faster and more accurate diagnostic solutions is contributing to market growth. As public health strategies focus on early detection and prevention of viral hepatitis, the hepatitis E diagnostic tests market is poised for substantial expansion.
SCOPE OF STUDY:
The report analyzes the Hepatitis E Diagnostic Tests market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (ELISA HEV IGM Tests Type, ELISA HEV IGG Tests Type, Rapid Diagnostics Tests Type, Polymerase Chain Reaction Type); End-Use (Hospitals End-Use, Diagnostics Laboratories End-Use, Blood Banks End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.